Synergy CHC Corp.
2.2600-0.14 (-5.83%)
Oct 29, 4:00:01 PM EDT · NasdaqCM · SNYR · USD
Key Stats
Market Cap
25.29MP/E (TTM)
5.95Basic EPS (TTM)
0.38Dividend Yield
0%Recent Filings
8-K
Synergy closes $4.375M offering
Synergy CHC Corp. closed its public offering on August 27, 2025, selling 1,750,000 shares at $2.50 each for $4.375 million in gross proceeds. Underwritten by Bancroft Capital, the deal includes a 45-day option for 262,500 more shares and warrants for 52,500 shares exercisable after 180 days. Net proceeds will fund working capital and general purposes. Yet dilution looms for shareholders.
8-K
EG America rollout announced
Synergy CHC Corp. secured a major retail distribution deal with EG America, the sixth-largest U.S. convenience chain, for its FOCUSfactor Focus + Energy beverage line. The Q4 2025 rollout across over 1,600 high-traffic locations nationwide expands the product's reach in the surging functional beverage and brain health markets. This partnership aligns with Synergy's strategy to grow its beverage business through mass, grocery, convenience, and specialty channels. Momentum builds.
8-K
Q2 profit surges 125%
Synergy CHC Corp. reported Q2 2025 revenue of $8.1 million, up 1% from $8.0 million last year, with gross margin surging to 76.7% from 69.5% thanks to $1.4 million in license revenue. Net income more than doubled to $1.5 million, or $0.17 per share, marking the tenth straight profitable quarter. The company refinanced $20 million in debt maturing in 2029 and expanded FOCUSfactor licensing to Turkey. Profitability persists.
10-Q
Q2 FY2025 results
Synergy CHC Corp. posted Q2 revenue of $8.1M, edging up 1.4% y/y from $8.0M yet dipping 5% q/q (derived), buoyed by $1.4M in new license revenue offsetting a 16% y/y drop in product sales to $6.7M due to a one-time 2024 sell-in. Gross margins swelled to 77% from 69% y/y, fueling operating income of $1.6M, flat y/y, while net income jumped to $1.5M from $0.7M, aided by a $2.2M gain on loan settlements that trimmed net interest costs. YTD revenue fell 6% to $16.3M, but net income rose 90% to $2.3M with EPS steady at $0.27 on 8.7M diluted shares; cash used in operations eased to $0.9M from $1.1M, with free cash flow unavailable as capex not disclosed. The $17.5M May 2025 term loan at 12.83% (SOFR+8.5%, maturing 2029) refinanced debts, leaving $25.0M long-term notes and $1.5M cash, while settling shareholder notes via $0.9M warrants. Customer concentration lingers as a risk.
8-K
Synergy secures key retail wins
Synergy CHC Corp. announced major North American retail expansions for its FOCUSfactor supplements and functional beverages on June 30, 2025. Core-Mark granted national authorization, enabling distribution to over 50,000 locations across the U.S. and Canada starting Q3 2025, while Walmart Canada will launch two supplement SKUs nationally in Q4 2025. Additional wins with Metro, Energy North Group, and Downey Wholesale boost access in grocery, convenience, and independent channels. This scales Synergy's brain health and clean energy products efficiently.
BHC
Bausch Health Companies Inc.
5.90-0.29
CAH
Cardinal Health, Inc.
164.47+1.68
COR
Cencora, Inc.
333.17-2.47
COSM
Cosmos Health Inc.
0.93-0.01
HLYK
HealthLynked Corp.
1.63+0.00
HYEX
HEALTHY EXTRACTS INC.
2.10+0.09
PBH
Prestige Consumer Healthcare In
60.71-1.32
SYIN
Synbio International Inc.
0.00-0.00
YCBD
cbdMD, Inc.
0.95-0.08
YJGJ
Yijia Group Corp.
1.61+0.00